C5 and paroxysmal nocturnal hemoglobinuria: Eculizumab, an anti-C5 monoclonal antibody approved for the treatment of aHUS and PNH, revolutionized the treatment of TMA, with safe and effective inhibitors for different levels of complement cascade emerging.